IL-12 DNA + bupivacaine

IL-12 DNA + bupivacaine is an investigational combination therapy that includes a plasmid encoding interleukin-12 (IL-12) and the local anesthetic bupivacaine. The IL-12 DNA component acts as a genetic adjuvant, promoting Th1-type immune responses by inducing maturation of type 1 T helper cells, enhancing natural killer (NK) cell activity, and stimulating antigen-specific CD4+ and CD8+ T-cell proliferation. This approach aims to boost cellular immunity in the context of vaccination or immunotherapy[6][2]. Bupivacaine is an amide-type local anesthetic that blocks voltage-gated sodium channels on neurons, preventing nerve impulse conduction and providing local anesthesia at the injection site[3][5]. The combination may be used to enhance immune responses while minimizing injection pain or discomfort. This strategy has been explored in preclinical models and early-phase clinical trials for infectious diseases such as HIV and herpesvirus infections[2][6].